NASDAQ:ALQA - Alliqua Biomedical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.74 +0.03 (+1.75 %) (As of 11/15/2018 11:23 AM ET)Previous Close$1.71Today's Range$1.6239 - $1.7452-Week Range$1.55 - $2.78Volume9,791 shsAverage Volume40,621 shsMarket Capitalization$8.56 millionP/E Ratio-0.27Dividend YieldN/ABeta1.25 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania. Receive ALQA News and Ratings via Email Sign-up to receive the latest news and ratings for ALQA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALQA Previous Symbol CUSIPN/A Webwww.alliqua.com Phone215-702-8550 Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.90 Price-To-Earnings Trailing P/E Ratio-0.27 Forward P/E Ratio0.34 P/E GrowthN/A Sales & Book Value Annual Sales$19.57 million Price / Sales0.45 Cash FlowN/A Price / CashN/A Book Value$1.91 per share Price / Book0.91 Profitability EPS (Most Recent Fiscal Year)($6.49) Net Income$-25,700,000.00 Net Margins-90.48% Return on Equity-235.69% Return on Assets-119.08% Miscellaneous Employees60 Outstanding Shares5,010,000Market Cap$8.56 million OptionableNot Optionable Alliqua Biomedical (NASDAQ:ALQA) Frequently Asked Questions What is Alliqua Biomedical's stock symbol? Alliqua Biomedical trades on the NASDAQ under the ticker symbol "ALQA." When did Alliqua Biomedical's stock split? How did Alliqua Biomedical's stock split work? Alliqua Biomedical shares reverse split on Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Alliqua Biomedical stock prior to the reverse split would have 10 shares after the split. How were Alliqua Biomedical's earnings last quarter? Alliqua Biomedical Inc (NASDAQ:ALQA) posted its earnings results on Tuesday, August, 9th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.70) by $3.20. The firm earned $5.50 million during the quarter, compared to analysts' expectations of $5.38 million. Alliqua Biomedical had a negative return on equity of 235.69% and a negative net margin of 90.48%. View Alliqua Biomedical's Earnings History. When is Alliqua Biomedical's next earnings date? Alliqua Biomedical is scheduled to release their next quarterly earnings announcement on Thursday, November 15th 2018. View Earnings Estimates for Alliqua Biomedical. What price target have analysts set for ALQA? 1 brokers have issued 12-month target prices for Alliqua Biomedical's stock. Their forecasts range from $2.80 to $2.80. On average, they expect Alliqua Biomedical's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View Analyst Price Targets for Alliqua Biomedical. What is the consensus analysts' recommendation for Alliqua Biomedical? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alliqua Biomedical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alliqua Biomedical. Has Alliqua Biomedical been receiving favorable news coverage? News headlines about ALQA stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alliqua Biomedical earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Alliqua Biomedical's key competitors? Some companies that are related to Alliqua Biomedical include SANUWAVE Health (SNWV), AIT Therapeutics (AITB), PAVmed (PAVM), Lianluo Smart (LLIT), DarioHealth (DRIO), Titan Medical (TMDI), Hancock Jaffe Laboratories (HJLI), Valeritas (VLRX), CELLECT BIOTECH/S (APOP), Dynatronics (DYNT), Invivo Therapeutics (NVIV), Biostage (BSTG), Presbia (LENS), Neurometrix (NURO) and Viatar CTC Solutions (VRTT). Who are Alliqua Biomedical's key executives? Alliqua Biomedical's management team includes the folowing people: Mr. David Ian Johnson, Pres, CEO & Director (Age 60)Mr. Joseph M. Warusz, CFO, Treasurer & Sec. (Age 62)Dr. Phillip D. Forman M.D., DPM, Exec. VP of Clinical Affairs (Age 59)Mr. Gregory Robb, VP of Operations Who are Alliqua Biomedical's major shareholders? Alliqua Biomedical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (3.99%) and FNY Investment Advisers LLC (3.99%). Company insiders that own Alliqua Biomedical stock include Bradford Barton, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis and Mark T Wagner. View Institutional Ownership Trends for Alliqua Biomedical. Which major investors are buying Alliqua Biomedical stock? ALQA stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and FNY Investment Advisers LLC. Company insiders that have bought Alliqua Biomedical stock in the last two years include Bradford Barton, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis and Mark T Wagner. View Insider Buying and Selling for Alliqua Biomedical. How do I buy shares of Alliqua Biomedical? Shares of ALQA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Alliqua Biomedical's stock price today? One share of ALQA stock can currently be purchased for approximately $1.74. How big of a company is Alliqua Biomedical? Alliqua Biomedical has a market capitalization of $8.56 million and generates $19.57 million in revenue each year. The company earns $-25,700,000.00 in net income (profit) each year or ($6.49) on an earnings per share basis. Alliqua Biomedical employs 60 workers across the globe. What is Alliqua Biomedical's official website? The official website for Alliqua Biomedical is http://www.alliqua.com. How can I contact Alliqua Biomedical? Alliqua Biomedical's mailing address is 2150 CABOT BLVD WEST SUITE B, LANGHORNE PA, 19047. The company can be reached via phone at 215-702-8550 or via email at [email protected] MarketBeat Community Rating for Alliqua Biomedical (NASDAQ ALQA)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 276 (Vote Outperform)Underperform Votes: 171 (Vote Underperform)Total Votes: 447MarketBeat's community ratings are surveys of what our community members think about Alliqua Biomedical and other stocks. Vote "Outperform" if you believe ALQA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALQA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: How is a Moving Average Calculated?